and 37 other countries. David Gram a Food and Drug Administration drug safety expert that criticized the FDA’s handling of Vioxx says the new research “raises red flags” and “There’s no reason to think (Arcoxia) suffers from the same problem.”

The good news is there are several other drugs in the same category as Arcoxia that are proven to be s

In an attempt to replace its blockbuster painkilling drug Vioxx, Merk & Co. has released the new drug Arcoxia. The new drug however, is receiving bad reviews from many doctors who say that the drugs effectiveness is not worth its approval. Doctors point to three different studies revealed at the American Heart Association conference that show Arcoxia poses heart risks similar to the drug diclofenac, an older arthritis medication known to raise heart risks.

An article posted by the Journal of the American Medical Association displays even more bad news for Merk and Co. The article questions the cardiovascular safety of the drug diclofenac; the drug doctors say is comparable to Arcoxia. A Researcher pooled the results from 23 different studies in which people were deciding to take an NAISD. The data showed that diclofenac raised heart risks just as much as low dose Vioxx. The only medication with a greater risk was a larger dose of Vioxx.

This is bad news for Merk & Co. who is still reeling from the affects from the ban of Vioxx from the market. In a study of over 8,000 people it was found that Vioxx raised the risk of multiple cardiovascular problems such as heart attack, chest pain that was related to heart disease, sudden death, stroke, and blood clots more than 2X the traditional NAISD naproxen.

The new study on Arcoxia involved 34,701 arthritis patients in the US and 37 other countries. David Gram a Food and Drug Administration drug safety expert that criticized the FDA’s handling of Vioxx says the new research “raises red flags” and “There’s no reason to think (Arcoxia) suffers from the same problem.”

The good news is there are several other drugs in the same category as Arcoxia that are proven to be sa

a poses heart risks similar to the drug diclofenac, an older arthritis medication known to raise heart risks.

An article posted by the Journal of the American Medical Association displays even more bad news for Merk and Co. The article questions the cardiovascular safety of the drug diclofenac; the drug doctors say is comparable to Arcoxia. A Researcher pooled the results from 23 different studies in which people were deciding to take an NAISD. The data showed that diclofenac raised heart risks just as much as low dose Vioxx. The only medication with a greater risk was a larger dose of Vioxx.

This is bad news for Merk & Co. who is still reeling from the affects from the ban of Vioxx from the market. In a study of over 8,000 people it was found that Vioxx raised the risk of multiple cardiovascular problems such as heart attack, chest pain that was related to heart disease, sudden death, stroke, and blood clots more than 2X the traditional NAISD naproxen.

The new study on Arcoxia involved 34,701 arthritis patients in the US and 37 other countries. David Gram a Food and Drug Administration drug safety expert that criticized the FDA’s handling of Vioxx says the new research “raises red flags” and “There’s no reason to think (Arcoxia) suffers from the same problem.”

The good news is there are several other drugs in the same category as Arcoxia that are proven to be s

esearcher pooled the results from 23 different studies in which people were deciding to take an NAISD. The data showed that diclofenac raised heart risks just as much as low dose Vioxx. The only medication with a greater risk was a larger dose of Vioxx.

This is bad news for Merk & Co. who is still reeling from the affects from the ban of Vioxx from the market. In a study of over 8,000 people it was found that Vioxx raised the risk of multiple cardiovascular problems such as heart attack, chest pain that was related to heart disease, sudden death, stroke, and blood clots more than 2X the traditional NAISD naproxen.

The new study on Arcoxia involved 34,701 arthritis patients in the US and 37 other countries. David Gram a Food and Drug Administration drug safety expert that criticized the FDA’s handling of Vioxx says the new research “raises red flags” and “There’s no reason to think (Arcoxia) suffers from the same problem.”

The good news is there are several other drugs in the same category as Arcoxia that are proven to be s

from the market. In a study of over 8,000 people it was found that Vioxx raised the risk of multiple cardiovascular problems such as heart attack, chest pain that was related to heart disease, sudden death, stroke, and blood clots more than 2X the traditional NAISD naproxen.

The new study on Arcoxia involved 34,701 arthritis patients in the US and 37 other countries. David Gram a Food and Drug Administration drug safety expert that criticized the FDA’s handling of Vioxx says the new research “raises red flags” and “There’s no reason to think (Arcoxia) suffers from the same problem.”

The good news is there are several other drugs in the same category as Arcoxia that are proven to be s

and 37 other countries. David Gram a Food and Drug Administration drug safety expert that criticized the FDA’s handling of Vioxx says the new research “raises red flags” and “There’s no reason to think (Arcoxia) suffers from the same problem.”

The good news is there are several other drugs in the same category as Arcoxia that are proven to be safe however due to the inflated price of the drug companies, they can be come expensive. If you have a reoccurring prescription for an ailment such as arthritis you could spend thousands of dollars filling your prescription each year. If you would like help locating these medications at discount prices from 30% to 60% off the standard US cost, go to FreebeeForiegnPharmacy.com. Freebee has a database of foreign pharmacies that allows you to locate your discount medication from foreign pharmacies as well as compare their prices. Check out Freebee for more information on how to order from an online foreign pharmacy.